EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study

Marine Tschirhart, Anaïs Curtiaud, Ramy Abou Rjeily, Hamid Merdji, Julien Demiselle, François Severac, Daniel Guerin, Micael Caçao, Fatiha El Ghazouani, Eduardo Angles-Cano, Florence Toti, Ferhat Meziani und 1 weitere

Intensive Care Medicine · 2026-03 · 52 (3) · 456-465

DOI: 10.1007/s00134-026-08338-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, online erschienen am 25.02.2026. Verfasst von Marine Tschirhart und 12 weiteren Autor:innen. Beteiligte Einrichtung: INSERM (French National Institute of Health and Medical Research) UMR 1260, Regenerative Nanomedicine (RNM), Strasbourg, France. Hauptthemen laut MEDLINE: Disseminated Intravascular Coagulation, Sepsis, Plasminogen, Fibrinolysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: ADIRAL, Octapharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Sepsis-induced disseminated intravascular coagulation (DIC) is characterized by impaired fibrinolysis, partly due to neutrophil elastase-mediated plasminogen degradation. We aimed to evaluate whether plasminogen supplementation could restore fibrinolytic capacity in patients with sepsis-induced coagulopathy and in a murine model of septic DIC. METHODS: 60 patients with sepsis-induced coagulopathy were randomized to receive 12 mL/kg of placebo (NaCl 0.9%) or OctaplasLG®, a pathogen-inactivated pooled human plasma containing 2 µM plasminogen. Pre- and post-infusion levels of functional plasminogen, plasmin generation, and fibrinolysis markers (plasmin-antiplasmin complexes, plasminogen activator inhibitor-1, and tissue-type plasminogen activator) were measured. In parallel, in a sepsis-induced DIC model, transgenic TMpro/pro mice received either purified plasminogen or placebo. Functional plasminogen levels and plasmin generation were assessed via enzymatic assays. RESULTS: In patients, baseline plasminogen and plasmin generation were significantly lower than in healthy controls. OctaplasLG® significantly increased functional plasminogen (+ 46 nM [-96; 118] vs. -84 [-180; 27] nM, p < 0.05) and improved plasmin generation (0.12 [-0.25; 1.27] vs. -0.36 [-1.58; 0.12] fmol, p < 0.05). No changes were observed in plasmin-antiplasmin, plasminogen activator inhibitor-1, or tissue-type plasminogen activator levels. A non-significant trend toward reduced mortality was noted in patients receiving OctaplasLG® (42.3% vs. 60.0%). Septic DIC-mice also exhibited reduced functional plasminogen (100 [66-126] vs. 295 [268-343] nM) and impaired plasmin generation (1.8 [1.4-2.1] vs. 3.0 [2.8-3.3] fmol, p < 0.05), which were restored after plasminogen supplementation (plasminogen: 346 [287; 360] nM; plasmin generation: 4.1 [3.7; 5.5] fmol). CONCLUSION: Plasminogen supplementation restores fibrinolytic capacity, supporting its therapeutic potential in sepsis-induced DIC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disseminated Intravascular CoagulationSepsisPlasminogenFibrinolysisHumansPilot ProjectsMaleFemaleAnimalsMiceAgedMiddle AgedFibrinolysinDisease Models, Animal

Stichwörter der Autor:innen

CoagulopathyDisseminated intravascular coagulationFibrinolysisPlasminogenSepsis

Substanzen

PlasminogenFibrinolysin

Autor:innen und Institutionen

  • INSERM (French National Institute of Health and Medical Research) UMR 1260, Regenerative Nanomedicine (RNM), Strasbourg, France.
  • Université de Strasbourg (UNISTRA), Strasbourg, France.
  • Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Fédération Hospitalo-Universitaire TARGET, Strasbourg, France.
  • Université Paris Cité, INSERM UMR_S 1144, Équipe 4, Optimisation Thérapeutique en Neuropharmacologie, Paris, France.
  • Groupe Méthodes en Recherche Clinique (GMRC), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • INSERM (French National Institute of Health and Medical Research) UMR 1260, Regenerative Nanomedicine (RNM), Strasbourg, France. julie.helms@chru-strasbourg.fr.

ORCID-Profile: Julie Helms

Förderung

  • ADIRAL
  • Octapharma

Zitieren

APA

Tschirhart, M., Curtiaud, A., Abou Rjeily, R., Merdji, H., Demiselle, J., Severac, F., Guerin, D., Caçao, M., El Ghazouani, F., Angles-Cano, E., Toti, F., Meziani, F., & Helms, J. (2026). Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study. Intensive Care Medicine, 52(3), 456-465. https://doi.org/10.1007/s00134-026-08338-0

Vancouver

Tschirhart M, Curtiaud A, Abou Rjeily R, Merdji H, Demiselle J, Severac F, et al. Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study. Intensive Care Medicine. 2026;52(3):456-465. doi:10.1007/s00134-026-08338-0

BibTeX
@article{Tschirhart2026,
  author = {Tschirhart, Marine and Curtiaud, Anaïs and Abou Rjeily, Ramy and Merdji, Hamid and Demiselle, Julien and Severac, François and Guerin, Daniel and Caçao, Micael and El Ghazouani, Fatiha and Angles-Cano, Eduardo and Toti, Florence and Meziani, Ferhat and Helms, Julie},
  title = {Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study},
  journal = {Intensive Care Medicine},
  year = {2026},
  volume = {52},
  number = {3},
  pages = {456--465},
  doi = {10.1007/s00134-026-08338-0}
}
Kostenlos starten →